Aurobindo gets US FDA nod for generic osteoporosis drug- market size of USD 404 millionThe approval by the US FDA for Raloxifene Hydrochloride tablets is for strength of 60 mg, which is bio and therapeutically equivalent to the reference listed drug product (RLD) Evista, 60 mg of Eli Lilly, the company said in a statement. The product has an estimated market size of USD 404 million for the 12 months ended June 2015, the company added, citing IMS data.
Read more…
Aurobindo gets US FDA nod for generic osteoporosis drug- market size of USD 404 million
| Subscribe To Our Free Newsletter |
